Toes R - Search Results

1

Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial.

Cope AP, Jasenecova M, Vasconcelos JC, Filer A, Raza K, Qureshi S, D'Agostino MA, McInnes IB, Isaacs JD, Pratt AG, Fisher BA, Buckley CD, Emery P, Ho P, Buch MH, Ciurtin C, van Schaardenburg D, Huizinga T, Toes R, Georgiou E, Kelly J, Murphy C, Prevost AT; APIPPRA study investigators. Cope AP, et al. Among authors: toes r. Lancet. 2024 Mar 2;403(10429):838-849. doi: 10.1016/S0140-6736(23)02649-1. Epub 2024 Feb 13. Lancet. 2024. PMID: 38364839 Free article. Clinical Trial.

2

Enhanced concentrations of interleukin 16 are associated with joint destruction in patients with rheumatoid arthritis.

Lard LR, Roep BO, Toes RE, Huizinga TW. Lard LR, et al. Among authors: toes re. J Rheumatol. 2004 Jan;31(1):35-9. J Rheumatol. 2004. PMID: 14705216

3

High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis.

Eyre S, Bowes J, Diogo D, Lee A, Barton A, Martin P, Zhernakova A, Stahl E, Viatte S, McAllister K, Amos CI, Padyukov L, Toes RE, Huizinga TW, Wijmenga C, Trynka G, Franke L, Westra HJ, Alfredsson L, Hu X, Sandor C, de Bakker PI, Davila S, Khor CC, Heng KK, Andrews R, Edkins S, Hunt SE, Langford C, Symmons D; Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate; Wellcome Trust Case Control Consortium; Concannon P, Onengut-Gumuscu S, Rich SS, Deloukas P, Gonzalez-Gay MA, Rodriguez-Rodriguez L, Ärlsetig L, Martin J, Rantapää-Dahlqvist S, Plenge RM, Raychaudhuri S, Klareskog L, Gregersen PK, Worthington J. Eyre S, et al. Among authors: toes re. Nat Genet. 2012 Dec;44(12):1336-40. doi: 10.1038/ng.2462. Epub 2012 Nov 11. Nat Genet. 2012. PMID: 23143596 Free PMC article.

4

Anti-carbamylated protein antibodies are present in arthralgia patients and predict the development of rheumatoid arthritis.

Shi J, van de Stadt LA, Levarht EW, Huizinga TW, Toes RE, Trouw LA, van Schaardenburg D. Shi J, et al. Arthritis Rheum. 2013 Apr;65(4):911-5. doi: 10.1002/art.37830. Arthritis Rheum. 2013. PMID: 23279976 Free article.

5

Low-avidity anticitrullinated protein antibodies (ACPA) are associated with a higher rate of joint destruction in rheumatoid arthritis.

Suwannalai P, Britsemmer K, Knevel R, Scherer HU, Levarht EW, van der Helm-van Mil AH, van Schaardenburg D, Huizinga TW, Toes RE, Trouw LA. Suwannalai P, et al. Among authors: toes re. Ann Rheum Dis. 2014 Jan;73(1):270-6. doi: 10.1136/annrheumdis-2012-202615. Epub 2013 Mar 5. Ann Rheum Dis. 2014. PMID: 23463689

6

Anti-citrullinated protein antibodies acquire a pro-inflammatory Fc glycosylation phenotype prior to the onset of rheumatoid arthritis.

Rombouts Y, Ewing E, van de Stadt LA, Selman MH, Trouw LA, Deelder AM, Huizinga TW, Wuhrer M, van Schaardenburg D, Toes RE, Scherer HU. Rombouts Y, et al. Ann Rheum Dis. 2015 Jan;74(1):234-41. doi: 10.1136/annrheumdis-2013-203565. Epub 2013 Oct 8. Ann Rheum Dis. 2015. PMID: 24106048

7

Anti-carbamylated protein (anti-CarP) antibodies precede the onset of rheumatoid arthritis.

Shi J, van de Stadt LA, Levarht EW, Huizinga TW, Hamann D, van Schaardenburg D, Toes RE, Trouw LA. Shi J, et al. Ann Rheum Dis. 2014 Apr;73(4):780-3. doi: 10.1136/annrheumdis-2013-204154. Epub 2013 Dec 13. Ann Rheum Dis. 2014. PMID: 24336334

8

Association of anti-carbamylated protein antibodies with long-term disability and increased disease activity in patients with early inflammatory arthritis: results from the Norfolk Arthritis Register.

Humphreys J, Verheul M, Barton A, Fu B, Toes R, Symmons D, Trouw L, Verstappen S. Humphreys J, et al. Among authors: toes r. Lancet. 2015 Feb 26;385 Suppl 1:S44. doi: 10.1016/S0140-6736(15)60359-2. Lancet. 2015. PMID: 26312866

9

Antibodies against collagen type II are not a general marker of acute arthritis onset.

Manivel VA, van der Woude D, Toes R, Filer A, Raza K, Rönnelid J. Manivel VA, et al. Among authors: toes r. Ann Rheum Dis. 2018 Jun;77(6):954-956. doi: 10.1136/annrheumdis-2017-211974. Epub 2017 Aug 24. Ann Rheum Dis. 2018. PMID: 28839108 No abstract available.

10

Rheumatoid factors do not preferentially bind to ACPA-IgG or IgG with altered galactosylation.

Falkenburg WJJ, Kempers AC, Dekkers G, Ooijevaar-de Heer P, Bentlage AEH, Vidarsson G, van Schaardenburg D, Toes REM, Scherer HU, Rispens T. Falkenburg WJJ, et al. Rheumatology (Oxford). 2017 Nov 1;56(11):2025-2030. doi: 10.1093/rheumatology/kex284. Rheumatology (Oxford). 2017. PMID: 28977504

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

485 results

Search Page